Lithium citrate
Brand names: Li-Liquid, Priadel liquid
Lithium citrate is a lithium salt used as a mood stabiliser in the treatment and prophylaxis of bipolar disorder and recurrent depression, and to control mania.
Adult dose
Dose adjustments
Mild and moderate renal insufficiency: serum lithium levels must be closely monitored and the dose adjusted accordingly to keep levels within the recommended range; if very regular and close monitoring of serum lithium and plasma creatinine is not possible, lithium should not be prescribed in this population. Contraindicated in severe renal insufficiency. (SPC 4.2 / 4.4 / 4.3)
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- History of hypersensitivity to lithium or to any of the excipients
- Severe renal insufficiency
- Cardiac disease and cardiovascular insufficiency
- Untreated hypothyroidism
- Low body sodium levels - including dehydrated patients, those on low sodium diets, and those with Addison's disease
- Brugada syndrome or family history of Brugada syndrome
- Breast-feeding
Side effects
- Tremor, especially fine hand tremor; also ataxia, slurred speech, dizziness, giddiness and memory impairment - symptoms that may result in falls
- Polydipsia and/or polyuria, nephrogenic diabetes insipidus; interstitial renal changes on long-term treatment
- Thyroid disturbance - euthyroid goitre and/or hypothyroidism, thyrotoxicosis; hypercalcaemia (very frequent) and hyperparathyroidism
- Gastrointestinal - nausea, vomiting, diarrhoea, abdominal discomfort, dry mouth, taste disorder, anorexia (mild GI effects often settle after the first few days)
- Cardiac - bradycardia and sinus node dysfunction, hypotension, reversible T-wave flattening or inversion, QT prolongation, AV block, unmasking of Brugada syndrome
- Weight increase, hyperglycaemia, thirst; leucocytosis; skin reactions including acneform eruptions and aggravation of psoriasis
Interactions
- Diuretics - diuretic-induced sodium loss reduces lithium clearance and increases serum lithium; monitor electrolytes and lithium more frequently and reduce the dose (US label 7.1; eMC 4.4 warns about drugs likely to upset electrolyte balance)
- NSAIDs - decrease renal blood flow and increase serum lithium concentrations; monitor more frequently and reduce the dose (US label 7.1)
- Renin-angiotensin system antagonists and metronidazole - may increase lithium serum concentrations (US label 7)
- Serotonergic agents - increased risk of serotonin syndrome (US label 7.1)
- Antipsychotics - neurologic adverse reactions ranging from extrapyramidal symptoms to neuroleptic malignant syndrome (US label 7.1)
- Salt/water depletion of any cause (vomiting, diarrhoea, excessive sweating, severe dieting) raises lithium concentrations - monitor closely and adjust (eMC 4.4)
Clinical monograph
How it works
Its precise mechanism is uncertain, but lithium is thought to modulate neuronal signal transduction, including effects on second-messenger systems, to stabilise mood.
Prescribing in practice
- Lithium has a narrow therapeutic index, and toxicity can be life-threatening, so serum lithium concentrations must be monitored and patients warned about precipitants such as dehydration, infection and interacting drugs.
- Different lithium preparations vary in bioavailability, so the brand should not be changed without re-checking serum levels.
- Renal, thyroid and cardiac function require assessment before and during treatment, as lithium can affect the kidneys and thyroid.
Monitoring
Monitor serum lithium concentrations regularly, together with renal and thyroid function, and review for signs of toxicity such as tremor, vomiting, diarrhoea and confusion.
Counselling the patient
- Maintain a consistent fluid and salt intake and avoid becoming dehydrated.
- Carry a lithium alert card and attend for blood tests as scheduled.
- Seek urgent advice for coarse tremor, persistent vomiting, diarrhoea or drowsiness.
Evidence & guidelines
Lithium is a long-established, evidence-based mood stabiliser recommended by NICE for bipolar disorder, with the MHRA emphasising the need for routine monitoring.
Reference: NICE CG185; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185